Literature DB >> 35835615

Contributions of the NICHD neonatal research network's generic database to documenting and advancing the outcomes of extremely preterm infants.

Edward F Bell1, Barbara J Stoll2, Nellie I Hansen3, Myra H Wyckoff4, Michele C Walsh5, Pablo J Sánchez6, Matthew A Rysavy7, Jenna H Gabrio8, Stephanie W Archer5, Abhik Das9, Rosemary D Higgins10.   

Abstract

The Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network (NRN) maintains a database of extremely preterm infants known as the Generic Database (GDB). Begun in 1987, this database now includes more than 91,000 infants, most of whom are extremely preterm (<29 weeks gestation). The GDB has been the backbone of the NRN, providing high quality, prospectively collected data to study the changing epidemiology of extreme prematurity and its outcomes over time. In addition, GDB data have been used to generate hypotheses for prospective studies and to develop new clinical trials by providing information about the numbers and characteristics of available subjects and the expected event rates for conditions and complications to be studied. Since its inception, the GDB has been the basis of more than 200 publications in peer-reviewed journals, many of which have had a significant impact on the field of neonatology.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Generic Database; NICHD; Neonatal Research Network; Neonatal clinical trials

Mesh:

Year:  2022        PMID: 35835615      PMCID: PMC9529835          DOI: 10.1016/j.semperi.2022.151635

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.311


  59 in total

1.  Neonatal Morbidities among Moderately Preterm Infants with and without Exposure to Antenatal Corticosteroids.

Authors:  Sanjay Chawla; Girija Natarajan; Dhuly Chowdhury; Abhik Das; Michele Walsh; Edward F Bell; Abbot R Laptook; Krisa Van Meurs; Carl T D'Angio; Barbara J Stoll; Sara B DeMauro; Seetha Shankaran
Journal:  Am J Perinatol       Date:  2018-04-27       Impact factor: 1.862

Review 2.  The problems of moderate preterm infants.

Authors:  Andrea N Trembath; Allison H Payne; Tarah T Colaizy; Edward F Bell; Michele C Walsh
Journal:  Semin Perinatol       Date:  2016-09-13       Impact factor: 3.300

3.  Delivery Room Resuscitation and Short-Term Outcomes in Moderately Preterm Infants.

Authors:  Monika Bajaj; Girija Natarajan; Seetha Shankaran; Myra Wyckoff; Abbot R Laptook; Edward F Bell; Barbara J Stoll; Waldemar A Carlo; Betty R Vohr; Shampa Saha; Krisa P Van Meurs; Pablo J Sanchez; Carl T D'Angio; Rosemary D Higgins; Abhik Das; Nancy Newman; Michele C Walsh
Journal:  J Pediatr       Date:  2018-01-03       Impact factor: 4.406

4.  Between-hospital variation in treatment and outcomes in extremely preterm infants.

Authors:  Matthew A Rysavy; Lei Li; Edward F Bell; Abhik Das; Susan R Hintz; Barbara J Stoll; Betty R Vohr; Waldemar A Carlo; Seetha Shankaran; Michele C Walsh; Jon E Tyson; C Michael Cotten; P Brian Smith; Jeffrey C Murray; Tarah T Colaizy; Jane E Brumbaugh; Rosemary D Higgins
Journal:  N Engl J Med       Date:  2015-05-07       Impact factor: 91.245

5.  Antecedents and Outcomes of Abnormal Cranial Imaging in Moderately Preterm Infants.

Authors:  Girija Natarajan; Seetha Shankaran; Shampa Saha; Abbot Laptook; Abhik Das; Rosemary Higgins; Barbara J Stoll; Edward F Bell; Waldemar A Carlo; Carl D'Angio; Sara B DeMauro; Pablo Sanchez; Krisa Van Meurs; Betty Vohr; Nancy Newman; Ellen Hale; Michele Walsh
Journal:  J Pediatr       Date:  2018-02-01       Impact factor: 4.406

6.  Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants.

Authors:  Barbara J Stoll; Nellie Hansen; Avroy A Fanaroff; Linda L Wright; Waldemar A Carlo; Richard A Ehrenkranz; James A Lemons; Edward F Donovan; Ann R Stark; Jon E Tyson; William Oh; Charles R Bauer; Sheldon B Korones; Seetha Shankaran; Abbot R Laptook; David K Stevenson; Lu-Ann Papile; W Kenneth Poole
Journal:  N Engl J Med       Date:  2002-07-25       Impact factor: 91.245

7.  A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network.

Authors:  J D Horbar; L L Wright; R F Soll; E C Wright; A A Fanaroff; S B Korones; S Shankaran; W Oh; B D Fletcher; C R Bauer
Journal:  J Pediatr       Date:  1993-11       Impact factor: 4.406

8.  Aggressive vs. conservative phototherapy for infants with extremely low birth weight.

Authors:  Brenda H Morris; William Oh; Jon E Tyson; David K Stevenson; Dale L Phelps; T Michael O'Shea; Georgia E McDavid; Rebecca L Perritt; Krisa P Van Meurs; Betty R Vohr; Cathy Grisby; Qing Yao; Claudia Pedroza; Abhik Das; W Kenneth Poole; Waldemar A Carlo; Shahnaz Duara; Abbot R Laptook; Walid A Salhab; Seetha Shankaran; Brenda B Poindexter; Avroy A Fanaroff; Michele C Walsh; Maynard R Rasmussen; Barbara J Stoll; C Michael Cotten; Edward F Donovan; Richard A Ehrenkranz; Ronnie Guillet; Rosemary D Higgins
Journal:  N Engl J Med       Date:  2008-10-30       Impact factor: 91.245

9.  Neurodevelopmental and growth impairment among extremely low-birth-weight infants with neonatal infection.

Authors:  Barbara J Stoll; Nellie I Hansen; Ira Adams-Chapman; Avroy A Fanaroff; Susan R Hintz; Betty Vohr; Rosemary D Higgins
Journal:  JAMA       Date:  2004-11-17       Impact factor: 56.272

10.  Early CPAP versus surfactant in extremely preterm infants.

Authors:  Neil N Finer; Waldemar A Carlo; Michele C Walsh; Wade Rich; Marie G Gantz; Abbot R Laptook; Bradley A Yoder; Roger G Faix; Abhik Das; W Kenneth Poole; Edward F Donovan; Nancy S Newman; Namasivayam Ambalavanan; Ivan D Frantz; Susie Buchter; Pablo J Sánchez; Kathleen A Kennedy; Nirupama Laroia; Brenda B Poindexter; C Michael Cotten; Krisa P Van Meurs; Shahnaz Duara; Vivek Narendran; Beena G Sood; T Michael O'Shea; Edward F Bell; Vineet Bhandari; Kristi L Watterberg; Rosemary D Higgins
Journal:  N Engl J Med       Date:  2010-05-16       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.